(MENAFN- EIN Presswire)
Pulmonary Arterial Hypertension Treatment Market
The pulmonary arterial hypertension treatment market size is projected to reach $11,968.60 million by 2031, growing at a CAGR of 5.2% from 2021 to 2031.
The key factors that drive the growth of the pulmonary arterial hypertension treatment industry include rise in prevalence of pulmonary arterial hypertension cases” - Allied Market Research
WILMINGTON, DELAWARE , UNITED STATES, April 16, 2024 /EINPresswire / -- s per the report published by Allied Market Research, the global pulmonary arterial hypertension market generated $7.2 billion in 2021, and is expected to reach $12 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031. The report provides an in-depth analysis of top segments, changing market trends, value chains, key investment pockets, competitive scenarios, and regional landscape.
The report is an essential and helpful source of information for leading market players, investors, new entrants, and stakeholders in formulating new strategies for the future and taking steps to strengthen their position in the market.
Request Sample Copy of Report
The global pulmonary arterial hypertension market is segmented by drug type, type, route of administration, and region.
In 2021, the prostacyclin and prostacyclin analogs segment emerged as the largest contributor, comprising over half of the market share. This segment is anticipated to exhibit the most significant compound annual growth rate (CAGR) of 5.5% throughout the forecast period.
Regarding type, branded medications dominated the market revenue in 2021, representing over four-fifths of the market. Nevertheless, generics are forecasted to experience the highest CAGR of 5.7% from 2022 to 2031.
As for the route of administration, the oral segment held the majority share in 2021, accounting for almost two-thirds of the market. Furthermore, it is expected to demonstrate the highest CAGR of 5.6% during the forecast period.
For Purchase Inquiry-
The analysis of the global pulmonary arterial hypertension market encompasses regions including North America, LAMEA, Asia-Pacific, and Europe. North America dominated the market landscape in 2021, capturing over two-fifths of the market share. Conversely, the Asia-Pacific region is forecasted to achieve the most substantial compound annual growth rate (CAGR) of 7.2% from 2022 to 2031.
Key Market Players
Bayer AG
GlaxoSmithKline Plc
Gilead Sciences, Inc.
Johnson & Johnson
Lupin Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Sun Pharmaceutical Industries, Ltd.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Viatris Inc.
KEY FINDINGS OF THE STUDY
By drug type, the prostacyclin and prostacyclin analogs segment was the highest contributor to the pulmonary arterial hypertension treatment market share in 2021.
By type, the branded segment was the highest contributor to the market in 2021, and the generic segment is expected to continue this trend during the forecast period
Depending on route of administration, the oral segment was highest contributor in 2021 and is expected to grow at the fastest CAGR during the forecast period.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pulmonary arterial hypertension treatment market analysis from 2021 to 2031 to identify the prevailing pulmonary arterial hypertension treatment market opportunity.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pulmonary arterial hypertension treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pulmonary arterial hypertension treatment market trends, key players, market segments, application areas, and market growth strategies.
David Correa
Allied Market Research
+1 5038946022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
MENAFN16042024003118003196ID1108099716
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.